US Patent Issued to Akebia Therapeutics on May 19 for "Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer" (Massachusetts Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,629,357, issued on May 19, was assigned to Akebia Therapeutics Inc. (Cambridge, Mass.).

"Treatment of viral infections, of organ injury, and of related conditions using a HIF prolyl hydroxylase inhibitor or a HIF-alpha stabilizer" was invented by Steven Burke (Cambridge, Mass.) and Michael Rabinowitz (Cambridge, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating/preventing a disease or condition in patients in need thereof, such as a patient...